Titre :
|
Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. (1996)
|
Auteurs :
|
L. VON HERTZEN ;
R. ISOAHO ;
S.L. KIVELA ;
R. KOSKINEN ;
P. LAIPPALA ;
M. LEINONEN ;
P. SAIKKU ;
M. TOYRYLA
|
Type de document :
|
Article
|
Dans :
|
International journal of epidemiology (vol. 25, n° 3, 1996)
|
Pagination :
|
658-664
|
Langues:
|
Anglais
|
Mots-clés :
|
Epidémiologie
;
Etiologie
;
Bactériose
;
Infection
;
Bactérie
;
Personne âgée
;
Homme
;
Finlande
;
Europe
;
Appareil respiratoire [pathologie]
|
Résumé :
|
[BDSP. Notice produite par INIST TXZhuR0x. Diffusion soumise à autorisation]. Background. The significance of persistent or recurrent respiratory infections in adult life for the development of chronic obstructive pulmonary disease (COPD) is still to a large extent unknown. A few clinical and experimental animal studies suggest that peripheral airways diseases may be due to the cumulative effects of recurrent respiratory infections over an extended period. Methods. C. pneumoniae-specific IgG and IgA antibody levels were determined in two elderly groups of male patients with COPD and in control subjects without the disease. The first group (N=36) consisted of patients who were hospitalized due to an acute exacerbation of COPD. The second group of patients (N=54) and the controls (N=321) were participants in a community survey on respiratory diseases in the elderly. The criteria for seropositivity were defined as an IgG titre of 32 and an IgA titre of 16. Results. 89% of the hospitalized patients (group 1) and 66% of the non-hospitalized patients (group II) were IgA-seropositive as compared to 55% of the controls. Derived from the logistic regression analysis, the odds ratio (OR) was 7.4 (95% Cl : 2.1-25.7) between group I and the controls and 1.5 (0.7-2.9) between group II and the controls. Furthermore, the difference in the age-adjusted geometric mean titres (GMT) of IgA antibodies between the group I and the controls was significant (53.0 for the patients versus 19.1 for the controls). (...)
|